~ $4M

in Grants from NIA, NINDS, NIDA

Preclinical Success

Multiple CNS Indications

10 +

Patents / Publications

Independent Validation

Problem: The NMDA Receptor Paradox

Receptors outside synapses (Extrasynaptic receptors)

• Pathological activation

• Pro-death signaling

• Must be BLOCKED

Receptors inside synapses (Synaptic receptors)

• Normal brain function

• Pro-survival signaling

• Must be PRESERVED

Why Traditional NMDA Blockers Fail?

• Small molecules diffuse everywhere

• Cannot distinguish synaptic vs extrasynaptic receptors

• Block both beneficial and harmful signaling

• Cause side effects and have limited efficacy

Precision by design

Our nanotherapeutics are just large enough to bypass synaptic clefts yet small enough to be distributed throughout the brain, selectively blocking extrasynaptic NMDA receptors while preserving normal neural communication.

Our Approach: Thinking outside the synapse

Safe, efficient, durable

Our nanotherapeutics are rationally engineered from FDA-approved components to achieve a superior therapeutic window, with safety and efficacy validated in multiple preclinical studies.

Pipeline

Alzheimer's Disease

Opioid Use Disorder

Preventing addiction

Easing withdrawal

Reducing craving

Sustaining recovery

Huntington's Disease

Protecting neurons

Enhancing memory

Suppressing inflammation

Reducing amyloid-β burden

Protecting Neurons

Restoring motor function

Suppressing inflammation

Reducing mHTT aggregates